Skip to content
Clinical Trials – home
VerifiedinfoResponsive

Region Oestergoetland

Sweden Universitetssjukhuset I Linkoping, 581 85 Linkoping, Sweden

  • 8 trials recruiting
  • Endometrial cancer · Atrial fibrillation · Breast cancer female
  • Adults and children

About Specializations

Region Oestergoetland in Linkoping, Sweden specialises in clinical trials of conditions such as Endometrial cancer, Atrial fibrillation, Breast cancer female, Malignant melanoma stage III, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology

The medical center is at the forefront of oncology research, focusing on innovative treatments for various cancers. The center's work in this field is driven by a commitment to improving patient outcomes through cutting-edge therapies and personalized medicine.

  • Generalized Mantle Cell Lymphoma
  • Ovarian Cancer
  • Uveal Melanoma Liver Metastases
  • Acute Myeloid Leukemia
  • Cutaneous Malignant Melanoma

By integrating clinical trials with translational research, the center is advancing the understanding of cancer biology and developing novel therapeutic strategies.

Gastroenterology

Specializing in gastroenterology, the center conducts pioneering research to address complex digestive disorders. The focus is on enhancing diagnostic techniques and therapeutic interventions to improve patient care.

  • Crohn's Disease
  • Ulcerative Colitis
  • Resected Pancreatic Ductal Adenocarcinoma

Through collaborative efforts, the center is developing innovative treatments that aim to improve quality of life for patients with chronic gastrointestinal conditions.

Cardiology

The center excels in cardiology research, focusing on the prevention and treatment of cardiovascular diseases. By leveraging advanced technologies and clinical expertise, the center is making significant strides in this critical field.

  • Coronary Artery Disease
  • Atrial Fibrillation
  • Heart Failure with Preserved Ejection Fraction

Research efforts are directed towards understanding the underlying mechanisms of heart diseases and developing effective therapeutic interventions.

Endocrinology

In the realm of endocrinology, the center is dedicated to advancing the treatment of metabolic and hormonal disorders. The research is aimed at improving patient outcomes through innovative therapies and personalized care.

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Thyroid Eye Disease

The center's research initiatives are focused on understanding the pathophysiology of endocrine disorders and developing novel treatment modalities.

Nephrology

Leading in nephrology research, the center is committed to improving the diagnosis and treatment of kidney diseases. The research is focused on innovative approaches to enhance renal function and patient care.

  • C3 Glomerulopathy
  • IgA Nephropathy

Through cutting-edge research, the center aims to develop new therapies that can significantly improve the quality of life for patients with chronic kidney conditions.

Neurology

The center's neurology research is dedicated to understanding and treating neurological disorders. The focus is on developing innovative therapies to improve patient outcomes and quality of life.

  • Major Depressive Disorder
  • Facial Nerve Palsy

By integrating clinical research with advanced neuroscience, the center is at the forefront of developing new treatments for complex neurological conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Universitetssjukhuset I Linkoping581 85 LinkopingSweden
Recruiting now
8 trials
Conditions studied
22
Partner status
Verified

More sites in LinkopingSweden

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

21 clinical trials

Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Tamoxifen
  • Sponsor:Karolinska Institutet
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Karolinska University Hospital
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:The University Of Birmingham
Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Glaxosmithkline Research & Development Limited
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Karolinska University Hospital
Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Karolinska University Hospital
Registered drug
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:Asparaginase
  • Sponsor:Princess Maxima Center For Pediatric Oncology
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Lixudebart
  • Sponsor:Alentis Therapeutics AG
Countries:SwedenSweden
  • Participants:65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Region Skane
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Karolinska University Hospital
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG
Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:University Of Cologne
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).